Stock AnalizUNITED THERAPEUTICS Corp UTHR
Biotechnology: Pharmaceutical Preparations · IPO 1999 · data as of November 13, 2026
UNITED THERAPEUTICS Corp (UTHR) is a healthcare company listed in the US with a market value of about $25.2B. In the twelve months to September 30, 2026 it had revenue of $3.2B and net income of $1.2B, a net margin of 38.6%.
Its overall Stock Analiz score is 4.0 out of 5 (excellent). The strongest part is future growth (5/5); the weakest is shareholder returns (2/5).
Key numbers: a P/E of 22.3, a price to free cash flow of 29.0, 5-year revenue growth of 16% a year, a 5-year average ROIC of 14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 45% below the current price.
Score: 4.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.7B | $1.6B |
| Net income | $1.2B | $1.3B | $1.2B | $985M | $727M | $476M | $515M | -$104M | $589M | $418M | $714M |
| Free cash flow | $867M | $1.0B | $1.1B | $748M | $664M | $477M | $696M | -$290M | $594M | $388M | $606M |
| EPS (diluted) | $26.49 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | $-2.39 | $13.39 | $9.31 | $15.25 |
| Net margin | 38.6% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | -7.2% | 36.2% | 24.2% | 44.6% |
| ROIC | — | 16.4% | 15.9% | 13.7% | 13.4% | 9.4% | 11.4% | -3.3% | 19.0% | 18.8% | 38.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $687.14, 16% above the current price; targets range from $390.00 to $850.00; the consensus rating is “Buy”; expected EPS is $24.96 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is UNITED THERAPEUTICS’s P/E ratio?
About 22.3, based on the last twelve months of diluted earnings per share (forward P/E about 22.1).
Is UNITED THERAPEUTICS stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 45% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does UNITED THERAPEUTICS pay a dividend?
Not currently.
Is UNITED THERAPEUTICS a good stock to buy?
We do not give buy or sell advice. UNITED THERAPEUTICS scores 4.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.